Levetiracetam (UCB-L059)

製品コードS1356 バッチS135602

印刷

化学情報

Chemical Structure Synonyms UCB-L059, SIB-S1 Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

C8H14N2O2
分子量 170.21 CAS No. 102767-28-2
Solubility (25°C)* 体外 DMSO 34 mg/mL (199.75 mM)
Water 34 mg/mL (199.75 mM)
Ethanol 34 mg/mL (199.75 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 Levetiracetam (UCB-L059, SIB-S1) is an anticonvulsant medication used to treat epilepsy. Levetiracetam (UCB-L059, SIB-S1) is an agonist of muscarinic acetylcholine receptors (mAChR). Levetiracetam modulates the presynaptic P/Q-type voltage-dependent calcium (Ca2+) channel.
in vitro Levetiracetam and related compounds bind to SV2A expressed in fibroblasts, indicating that SV2A is sufficient for Levetiracetam binding. [1] Levetiracetam irreversibly inhibits the high-voltage-activated (HVA) calcium current by approximately 18% on the average in freshly isolated CA1 hippocampal neurons of rats. Levetiracetam selectively inhibits N-type Ca2+ channels of CA1 pyramidal hippocampal neurons. [2] Levetiracetam reverses the inhibitory effect of DMCM on GABA-elicited currents in hippocampal neurons. [3]
in vivo Levetiracetam (17 mg/kg) produces a potent suppression of sound-induced clonic convulsions in mice, and this protective effect is significantly abolished by co-administration of the beta-carboline FG 7142. [3] Levetiracetam exerts potent anticonvulsant activity against both focal and secondarily generalized seizures in fully amygdala-kindled rats, i.e. , a model of temporal lobe epilepsy. Levetiracetam (13 mg/kg, 27 mg/kg or 54 mg/kg, i.p.) dose-dependently suppresses the increase in seizure severity and duration induced by repeated amygdala stimulation. Levetiracetam has a relatively short half-life (about 2-3 hours) in rats. [4] Levetiracetam (5.4 mg/kg to 96 mg/kg i.p.) dose-dependently inhibits both wild running and tonic-clonic convulsions in the audiogenic-seizure prone rat. Levetiracetam markedly suppresses spontaneous spike-and-wave discharge (SWD) but leaves the underlying EEG trace normal in the GAERS model of petit mal epilepsy. [5]

プロトコル(参考用のみ)

カスタマーフィードバック

Data from [Data independently produced by , , Sci Rep, 2016, 6:25705.]

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Levetiracetam Modulates Brain Metabolic Networks and Transcriptomic Signatures in the 5XFAD Mouse Model of Alzheimer's disease [ bioRxiv, 2023, 2023.11.10.566574] PubMed: 38014102
Pharmacokinetic, pharmacodynamic, and transcriptomic analysis of chronic levetiracetam treatment in 5XFAD mice: A MODEL-AD preclinical testing core study [ Alzheimers Dement (N Y), 2022, 8(1):e12329] PubMed: 36016830
A Low Dose of Aripiprazole Has the Strongest Sensitization Effect Among 19 Repositioned Bipolar Drugs in P-gp-overexpressing Drug-resistant Cancer Cells [ Anticancer Res, 2021, 41(2):687-697] PubMed: 33517273
AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro. [ PLoS One, 2019, 14(2):e0211644] PubMed: 30716120
Levetiracetam mitigates doxorubicin-induced DNA and synaptic damage in neurons [Manchon JF, et al. Sci Rep, 2016, 6:25705] PubMed: 27168474
Levetiracetam mitigates doxorubicin-induced DNA and synaptic damage in neurons [Manchon JF Sci Rep, 2016, 6:25705] PubMed: 27168474

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。